Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 16/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYBB | P04839 | 2/20 | 1.00 |
| ▸ | NOX5 | Q96PH1 | 2/20 | 1.00 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 1.00 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | STAT6 | P42226 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diphenyleneiodonium SCHEMBL29486373 | 1.00 | GPR3 (1.00) | GPR3MEN1KMT2ACYBBNOX5 | |
| Diphenyleneiodonium SCHEMBL30150802 | 0.97 | GPR3 (1.00) | GPR3MEN1KMT2ACYBBNOX5 | |
| Diphenyleneiodonium SCHEMBL10834144 | 0.97 | GPR3 (0.93) | GPR3MEN1KMT2ACYBBNOX5 | |
| Diphenyleneiodonium SCHEMBL159318 | 0.97 | GPR3 (1.00) | GPR3MEN1KMT2ACYBBNOX5 | |
| Diphenyleneiodonium SCHEMBL5547280 | 0.94 | GPR3 (0.94) | GPR3MEN1KMT2ACYBBNOX5 | |
| Diphenyleneiodonium SCHEMBL2057393 | 0.84 | GPR3 (0.73) | GPR3MEN1KMT2ACYBBNOX5 | |
| SCHEMBL8367212 | 0.81 | — | — | |
| Diphenyleneiodonium SCHEMBL3733575 | 0.80 | GPR3 (0.68) | GPR3MEN1KMT2ACYBBNOX5 | |
| Hydrochloric Acid SCHEMBL8168843 | 0.77 | — | — | |
| SCHEMBL795440 | 0.72 | GPR3 (0.54) | GPR3MEN1KMT2ACYBBNOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1446 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744663-A2 | SKIN COMPOSITION | Eaderm Co., Ltd. (JP) | 2026-05-20 | — | — | EP | claimed |
| US-20260098070-A1 | SMAGP FUSION MOLECULES AND METHODS OF USE THEREOF | DEM BIOPHARMA INC (US) | 2026-04-09 | — | — | US | claimed |
| EP-4646427-A2 | SMAGP FUSION MOLECULES AND METHODS OF USE THEREOF | DEM Biopharma, Inc. (US) | 2025-11-12 | — | — | EP | claimed |
| US-20250311689-A1 | SEEDLING GERMINATION AND GROWTH CONDITIONS | PIONEER HI-BRED INTERNATIONAL, INC. (US) | 2025-10-09 | — | — | US | claimed |
| US-20250262167-A1 | COMPOUNDS, TARGETS AND PATHWAYS FOR MACROPHAGE MODULATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2025-08-21 | — | — | US | claimed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| EP-3129102-B1 | IODONIUM ANALOGS AS INHIBITORS OF NADPH OXIDASES AND OTHER FLAVIN DEHYDROGENASES; FORMULATIONS THEREOF; AND USES THEREOF | US HEALTH (US) | 2025-06-18 | — | — | EP | claimed |
| WO-2025034879-A1 | COMPOSITIONS AND METHODS FOR TARGETING CYTOCHROME P450 REDUCTASE | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2025-02-13 | — | — | WO | claimed |
| WO-2024148295-A2 | SMAGP FUSION MOLECULES AND METHODS OF USE THEREOF | DEM BIOPHARMA, INC. (US) | 2024-07-11 | — | — | WO | claimed |
| WO-2024132860-A1 | DENTAL COMPOSITION COMPRISING A POLYMERIZATION SHRINKAGE MEDIATOR | DENTSPLY DETREY GMBH (DE) | 2024-06-27 | — | — | WO | claimed |
| EP-0765668-A1 | Extract of Iridaceas and composition containing it | L'OREAL (FR) | 1997-04-02 | — | — | EP | claimed |
| WO-1997009032-A1 | UTILIZATION OF AN EXTRACT OF A NON PHOTOSYNTHETIC FILAMENTARY BACTERIUM AND COMPOSITION CONTAINING SUCH EXTRACT | L'OREAL (FR) | 1997-03-13 | — | — | WO | claimed |
| WO-1997009056-A1 | EXTRACT OF IRIDACEAE AND COMPOSITIONS CONTAINING SUCH EXTRACT | L'OREAL (FR) | 1997-03-13 | — | — | WO | claimed |
| EP-0761204-A1 | Use of extracts of filamentous, non photosynthetic bacteria and the composition containing them | L'OREAL (FR) | 1997-03-12 | — | — | EP | claimed |
| WO-1996031217-A9 | INHIBITING RETROVIRAL REPLICATION | — | 1996-11-28 | — | — | WO | claimed |
| WO-1996031217-A1 | INHIBITING RETROVIRAL REPLICATION | DUKE UNIVERSITY (US) | 1996-10-10 | — | — | WO | claimed |
| WO-1996010402-A1 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | DYKE KNOX VAN (US) | 1996-04-11 | — | — | WO | claimed |
| WO-1996002241-A9 | USE OF NITROGEN OXIDE SPECIES AND ADDUCTS TO INHIBIT SKELETAL MUSCLE CONTRACTION | — | 1996-02-29 | — | — | WO | claimed |
| WO-1996002268-A1 | INHIBITION OF VIRUS BY NITRIC OXIDE | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1996-02-01 | — | — | WO | claimed |
| WO-1996002241-A1 | USE OF NITROGEN OXIDE SPECIES AND ADDUCTS TO INHIBIT SKELETAL MUSCLE CONTRACTION | DUKE UNIVERSITY (US) | 1996-02-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098070-A1 | SMAGP FUSION MOLECULES AND METHODS OF USE THEREOF | SELPLG, MPEG1, TNFSF11 | GPR3 3705/4885MEN1 2009/4885KMT2A 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.